

HJR162 INTRODUCED



1 HJR162
2 3P1PJZE-1
3 By Representatives Oliver, Reynolds
4 RFD: Rules
5 First Read: 24-Feb-26



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

HJR___ ENCOURAGING THE ALABAMA MEDICAID AGENCY TO EVALUATE THE OVERALL COSTS OF GLP-1 MEDICATIONS AND REPORT ITS FINDINGS.

WHEREAS, obesity is caused by a complex mix of environmental and biological factors, and it puts individuals at risk for other diseases, such as heart disease and diabetes; and

WHEREAS, in 2019, the Centers for Disease Control reported that obesity accounted for nearly \$173 billion in medical expenditures annually in the United States; GlobalData estimates that obesity has negatively impacted the State of Alabama's GDP by \$7.2 billion and annually impacts the state budget by over \$750 million; 2024 Behavioral Risk Factor Surveillance System data estimates the prevalence of obesity in Alabama is estimated at 38.9 percent for adults and 15.6 percent for children enrolled in the Women, Infants, and Children program in Alabama; and

WHEREAS, the Centers for Medicare and Medicaid Services recently launched two new drug pricing models that could positively impact Medicaid programs; the true impact will be known when the participating manufacturers and medications are announced by Spring 2026, approximately; and

WHEREAS, the Alabama Medicaid Agency estimates approximately 110,000 adult and child members may qualify



HJR162 INTRODUCED

29 for GLP-1 medications for weight management based on current
30 FDA labeling; it is important to determine whether GLP-1
31 medications could benefit Alabamians; now therefore,

32 BE IT RESOLVED BY THE LEGISLATURE OF ALABAMA, BOTH
33 HOUSES THEREOF CONCURRING, That the Alabama Medicaid Agency
34 is encouraged to:

35 (1) Determine actual savings that might exist in all
36 facets of the program should coverage of GLP-1 medications
37 be appropriate;

38 (2) Evaluate the overall costs of coverage of GLP-1
39 weight management medications in the context of potential
40 savings from new drug pricing models;

41 (3) Continue to have conversations with providers and
42 stakeholders in an effort to achieve optimal improved health
43 outcomes and cost savings for the State of Alabama should
44 coverage be appropriate; and

45 (4) Report its findings to the Legislature prior to
46 the 2027 Legislative Session.